Rui Pereira, Alberto N Araújo, Daniela Ribeiro, Ismael Rufino, Nuno Martinho, Rita C Guedes, Vera L M Silva, Eduarda Fernandes
{"title":"Design, Synthesis, and Evaluation of New Polyhydroxylated Bis-Chalcones as Potential COX-2 Selective Inhibitors.","authors":"Rui Pereira, Alberto N Araújo, Daniela Ribeiro, Ismael Rufino, Nuno Martinho, Rita C Guedes, Vera L M Silva, Eduarda Fernandes","doi":"10.1002/cmdc.202500784","DOIUrl":null,"url":null,"abstract":"<p><p>Selective inhibition of COX-2 is considered one of the best strategies for treating chronic inflammatory diseases. However, the currently available options still have significant side effects due to exacerbated selectivity. Bis-chalcone derivatives have shown promising anti-inflammatory properties with reduced side effects. In this study, a family of polyhydroxylated bis-chalcones was synthesized and tested in vitro for their ability to inhibit human COX-2 and COX-1 and to assess selectivity. To further understand their mechanism of action, inhibitory kinetic analysis and in silico molecular docking calculations were performed. The results showed that bis-chalcone 31, with hydroxy groups at positions 3' and 4' of the B rings and three hydroxy groups at the center, was the most active. It was recognized as a mixed-type inhibitor with balanced selectivity. With molecular docking, it was observed that this substitution pattern provided bis-chalcone 31 with additional bulk that hindered its access to the active pocket of COX-1 over COX-2. Also, compound 31 establishes additional hydrogen bonds within the COX-2 pocket that bis-chalcone 30 did not, therefore explaining the selectivity and superior potency of bis-chalcone 31. In conclusion, bis-chalcone 31 with multiple hydroxy groups in its structure shows promising properties for the design of new COX-2 selective inhibitors.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"21 8","pages":"e202500784"},"PeriodicalIF":3.4000,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110330/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500784","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Selective inhibition of COX-2 is considered one of the best strategies for treating chronic inflammatory diseases. However, the currently available options still have significant side effects due to exacerbated selectivity. Bis-chalcone derivatives have shown promising anti-inflammatory properties with reduced side effects. In this study, a family of polyhydroxylated bis-chalcones was synthesized and tested in vitro for their ability to inhibit human COX-2 and COX-1 and to assess selectivity. To further understand their mechanism of action, inhibitory kinetic analysis and in silico molecular docking calculations were performed. The results showed that bis-chalcone 31, with hydroxy groups at positions 3' and 4' of the B rings and three hydroxy groups at the center, was the most active. It was recognized as a mixed-type inhibitor with balanced selectivity. With molecular docking, it was observed that this substitution pattern provided bis-chalcone 31 with additional bulk that hindered its access to the active pocket of COX-1 over COX-2. Also, compound 31 establishes additional hydrogen bonds within the COX-2 pocket that bis-chalcone 30 did not, therefore explaining the selectivity and superior potency of bis-chalcone 31. In conclusion, bis-chalcone 31 with multiple hydroxy groups in its structure shows promising properties for the design of new COX-2 selective inhibitors.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.